Tag Archives: endpoint

aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint of change in mean daily oral corticosteroid dose at week 48, with a reduction to 2.79 mg for efzofitimod vs 3.52 mg for placebo (p=0.3313). However, …

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease1  Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren’s …